Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * BELANOFF JOSEPH K 2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY 3. Date of Earliest Transaction (Month/Day/Year) 06/02/2025 (Street) REDWOOD CITY, CA 94065 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 06/02/2025 S(1) 4,881 D $78.4211(2) 2,937,104 I Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3) Common Stock 06/02/2025 S(1) 3,050 D $79.4823(4) 2,934,054 I Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3) Common Stock 06/02/2025 S(1) 2,988 D $80.3017(5) 2,931,066 I Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3) Common Stock 06/02/2025 S(1) 1,820 D $81.3255(6) 2,929,246 I Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3) Common Stock 06/02/2025 S(1) 1,263 D $82.2634(7) 2,927,983 I Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3) Common Stock 06/02/2025 S(1) 4,631 D $83.4643(8) 2,923,352 I Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3) Common Stock 06/02/2025 S(1) 12,959 D $84.5715(9) 2,910,393 I Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3) Common Stock 06/02/2025 S(1) 8,408 D $85.0116(10) 2,901,985 I Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
BELANOFF JOSEPH K C/O CORCEPT THERAPEUTICS INCORPORATED 101 REDWOOD SHORES PARKWAY REDWOOD CITY, CA 94065	X		Chief Executive Officer

Signatures

/s/ Joseph Douglas Lyon, as attorney-in-fact for Joseph K. Belanoff.		06/04/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
(2)	Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $77.84 to $78.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
(3)	Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
(4)	Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $78.88 to $79.865 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
(5)	Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.90 to $80.8925 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
(6)	Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.92 to $81.78 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
(7)	Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.935 to $82.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
(8)	Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.96 to $83.95 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
(9)	Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.975 to $84.94 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
(10)	Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $85.00 to $85.31 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Remarks: The power of attorney under which this form was signed is on file with the Commission.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.